Location History:
- Ashland, MA (US) (2008 - 2011)
- Pennington, NJ (US) (2008 - 2012)
Company Filing History:
5 out of 850 
3 out of 3,684 
3 out of 5,450 
Years Active: 2008-2012
Title: Edwin A. Clark: Innovator in Cancer Treatment
Introduction
Edwin A. Clark is a notable inventor based in Pennington, NJ (US), recognized for his significant contributions to cancer treatment through innovative biomarker research. With a total of 8 patents, his work focuses on developing methods to predict therapeutic responses in cancer patients.
Latest Patents
One of his latest patents is titled "Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators." This invention provides a method for predicting the likelihood that a mammal will respond therapeutically to cancer treatment involving EGFR modulators. The method includes measuring the levels of biomarkers such as epiregulin and amphiregulin before and after exposure to the modulator, allowing for a better understanding of treatment efficacy.
Another significant patent is "Compositions and methods for the identification, assessment, prevention and therapy of human cancers." This invention focuses on identifying markers that indicate whether tumors are sensitive or resistant to therapeutic agents. It features sensitivity and resistance markers that can predict patient responses to treatment, enhancing personalized medicine approaches in oncology.
Career Highlights
Throughout his career, Edwin A. Clark has worked with prominent companies in the pharmaceutical industry, including Millennium Pharmaceuticals Limited and Bristol-Myers Squibb Company. His experience in these organizations has contributed to his expertise in cancer research and treatment development.
Collaborations
Edwin has collaborated with esteemed colleagues such as Robert C. Bast and Karen Lu, further enriching his research and innovation in the field of cancer therapeutics.
Conclusion
Edwin A. Clark's innovative work in cancer treatment through biomarker research has the potential to significantly improve therapeutic outcomes for patients. His contributions continue to shape the future of personalized medicine in oncology.